Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Medipharm Labs Corp

Healthcare CA LABS

0.07CAD
-0.005(6.67%)

Last update at 2026-06-05T20:00:00Z

Day Range

0.070.08
LowHigh

52 Week Range

0.060.11
LowHigh

Fundamentals

  • Previous Close 0.07
  • Market Cap27.62M
  • Volume1209140
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.59400M
  • Revenue TTM45.12M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 13.86M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.26700M -10.69400M -13.35900M -29.98900M -54.68800M
Minority interest - - - - 0.00000M
Net income -8.26700M -10.69400M -13.08300M -29.98300M -54.80100M
Selling general administrative 18.58M 19.81M 21.64M 18.45M 18.40M
Selling and marketing expenses 2.91M 3.04M 3.16M 6.30M 4.63M
Gross profit 13.97M 12.80M 5.86M -1.91400M -15.24600M
Reconciled depreciation 1.66M 2.60M 2.52M 2.87M 5.63M
Ebit -8.20400M -10.11800M -12.99400M -29.53300M -48.91600M
Ebitda -6.54400M -7.51800M -10.47800M -25.44000M -37.15100M
Depreciation and amortization 1.66M 2.60M 2.52M 4.09M 11.77M
Non operating income net other - - - - -
Operating income -8.40800M -10.80900M -18.25200M -29.53300M -48.91600M
Other operating expenses 53.53M 52.77M 51.31M 50.91M 64.72M
Interest expense 0.06M 0.58M 0.36M 0.03M 10.51M
Tax provision - 0.00000M -0.27600M -0.00600M 0.11M
Interest income 0.23M 0.12M 0.84M 0.46M 5.77M
Net interest income 0.17M 0.12M 0.47M 0.45M -10.28100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.27600M -0.00600M 0.11M
Total revenue 45.12M 41.96M 33.06M 22.12M 21.71M
Total operating expenses 22.38M 23.61M 24.11M 26.88M 27.76M
Cost of revenue 31.16M 29.16M 27.21M 24.03M 36.96M
Total other income expense net 0.14M 0.12M 4.89M -0.45600M -5.77200M
Discontinued operations - - - - -
Net income from continuing ops -8.26700M -10.69400M -13.08300M -29.98300M -54.80100M
Net income applicable to common shares - -10.69400M -13.08300M -29.98300M -54.80100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 45.74M 53.73M 63.94M 65.50M 92.36M
Intangible assets 0.68M 0.85M 1.03M 0.04M 0.04M
Earning assets - - - - -
Other current assets 1.11M 0.21M 2.89M 2.27M 4.75M
Total liab 9.93M 10.55M 10.93M 9.49M 9.21M
Total stockholder equity 35.81M 43.18M 53.01M 56.01M 83.15M
Deferred long term liab - - - - -
Other current liab 4.44M - 6.39M 4.00M 4.45M
Common stock 201.90M - 200.24M 191.26M 190.55M
Capital stock 201.90M 201.21M 200.24M 191.26M 190.55M
Retained earnings -169.37900M -187.42600M -176.73200M -163.64900M -129.34300M
Other liab - - - - 0.23M
Good will - - - - -
Other assets - - 0.00000M 0.00000M 0.88M
Cash 10.81M 11.69M 17.98M 24.14M 34.11M
Cash and equivalents - - - 24.14M 34.11M
Total current liabilities 9.93M 10.49M 10.86M 9.46M 8.88M
Current deferred revenue 0.57M - 0.11M 1.32M 1.32M
Net debt -10.60500M - -15.68600M -23.51300M -33.89400M
Short term debt 0.20M - 2.23M 0.60M 0.11M
Short long term debt 0.15M 0.26M 2.10M 0.52M -
Short long term debt total 0.20M - 2.29M 0.63M 0.22M
Other stockholder equity - - - 0.00000M 21.94M
Property plant equipment - - - 18.11M 25.89M
Total current assets 27.47M 33.08M 36.63M 47.34M 65.55M
Long term investments - - - - 0.00000M
Net tangible assets - - - - 83.10M
Short term investments - - 0.27M - -
Net receivables 7.53M 6.88M 5.87M 13.15M 17.35M
Long term debt - - - - 0.00000M
Inventory 8.02M 8.71M 9.90M 7.78M 10.98M
Accounts payable 4.71M 4.24M 2.13M 3.54M 2.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.29M - 29.49M 28.40M 21.94M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 1.00M - 0.88M
Deferred long term asset charges - - - - -
Non current assets total 18.27M 20.65M 27.30M 18.15M 26.81M
Capital lease obligations 0.05M 0.13M 0.19M 0.11M 0.22M
Long term debt total - - - 0.03M 0.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.41M 6.87M 5.16M 0.04M
Change to liabilities - - - - -8.10700M
Total cashflows from investing activities 4.62M 0.41M 6.87M 5.16M 0.04M
Net borrowings -0.19200M -2.25200M -0.94400M - -2.96200M
Total cash from financing activities -0.01800M -1.84700M -0.36800M 0.80M 27.80M
Change to operating activities - - - - 1.79M
Net income -8.26700M -10.69400M -13.08300M -29.98300M -54.80100M
Change in cash -0.88400M -6.29100M -6.16400M -9.96500M 14.20M
Begin period cash flow 11.69M 17.98M 24.14M 34.11M 19.91M
End period cash flow 10.81M 11.69M 17.98M 24.14M 34.11M
Total cash from operating activities -5.50400M -4.86100M -12.33900M -16.06900M -13.21300M
Issuance of capital stock - - - 0.00000M 30.92M
Depreciation 1.66M 2.60M 2.52M 2.87M 5.63M
Other cashflows from investing activities 4.72M 0.57M 2.08M 6.02M 0.82M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory 0.96M 0.80M 3.11M -0.10300M 11.16M
Change to account receivables -0.06300M -1.56300M 6.42M 3.62M 12.73M
Sale purchase of stock - 0.01M - 0.00000M 30.92M
Other cashflows from financing activities 0.17M 0.39M 0.58M 1.74M -0.15100M
Change to netincome - - - - 14.13M
Capital expenditures 0.10M 0.15M 0.47M 0.86M 0.78M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.02500M 1.65M 3.45M 6.25M 21.83M
Stock based compensation 1.34M 0.98M 2.03M 2.87M 2.40M
Other non cash items -0.21600M 0.60M -7.24900M 1.93M 11.61M
Free cash flow -5.60400M -5.01500M -12.81000M -16.93200M -13.99600M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LABS
Medipharm Labs Corp		 -0.005 6.67% 0.07 - 27.47 0.61 0.77 0.38 -1.8196
CURA
Curaleaf Holdings Inc.		 11.14 219.72% 16.21 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.18 2.46% 7.49 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 -0.05 1.28% 3.85 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 -0.33 4.57% 6.89 - 1000.00 1.28 0.53 1.08 -2.299

Reports Covered

Stock Research & News

View All

Profile

MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products. In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services. MediPharm Labs Corp. was founded in 2015 and is based in Barrie, Canada.

Medipharm Labs Corp

151 John Street, Barrie, ON, Canada, L4N 2L1

Key Executives

Name Title Year Born
Mr. Keith Strachan Co-Founder & Pres NA
Mr. Greg Hunter Chief Financial Officer NA
Mr. David A. Pidduck CEO & Director NA
Mr. Patrick McCutcheon Founder NA
Mr. Saravan Subramaniam VP of Operations & Supply Chain NA
Mr. Geoffrey Marr Exec. VP & Gen. Counsel NA
Mr. Brett Moon VP of Sales NA
Mr. Kirk Binns Exec. VP of Global Accounts NA
Mr. Nigel Dewsbury Head of Quality NA
Mr. Keith Strachan Co-Founder & President NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.